Neel Mistry

1 month ago | 2minutemedicine.com | Neel Mistry

1. Treatment failure was greater in the antibiotic group compared to appendicectomy group. 2. Significantly more patients in the antibiotic group reported mild-to-moderate adverse events. Evidence Rating Level: 1 (Excellent)Study Rundown: Recent studies have supported non-operative management of uncomplicated appendicitis in children instead of surgery. However, whether this approach is truly comparable to appendicectomy remains uncertain.

2 months ago | 2minutemedicine.com | Neel Mistry

1. Patients in the endovascular therapy group achieved greater functional outcomes at 90 days. 2. Endovascular therapy resulted in significantly decreased disability and overall mortality. Evidence Rating Level: 1 (Excellent)Study Rundown: Trials evaluating endovascular therapy for basilar artery occlusion have shown varying results. This inconsistency highlights the need for a comprehensive analysis to assess the therapy’s safety and efficacy.

2 months ago | 2minutemedicine.com | Neel Mistry

1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related adverse events were comparable between all three groups. Evidence Rating Level: 1 (Excellent)Study Rundown: Dermatomyositis is an autoimmune condition driven by type I interferon dysregulation. Current treatments fail to provide effective symptom control, highlighting the need for targeted therapies.

2 months ago | 2minutemedicine.com | Neel Mistry

1. The composite of all-cause mortality, myocardial infarction, and stroke favoured FFR-guided PCI plus TAVI compared to SAVR plus CABG. 2. All-cause mortality and life-threatening bleeding were lower in FFR-guided PCI plus TAVI. Evidence Rating Level: 1 (Excellent)Study Rundown: Many patients with severe aortic stenosis undergo surgical aortic valve replacement (SAVR) combined with coronary artery bypass grafting (CABG).

2 months ago | 2minutemedicine.com | Neel Mistry

1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission showed a similar trend between mirikizumab and placebo. Evidence Rating Level: 1 (Excellent)Study Rundown: Existing treatments for Crohn’s disease fail to achieve long-term remission in many patients. Mirikizumab, a monoclonal antibody targeting IL-23p19, has shown efficacy in ulcerative colitis and may hold promise for Crohn’s disease.